Summary Background Psoriasis is a chronic disease requiring long-term therapy. Objectives Physician- and patient-reported outcomes were evaluated through week 252 in VOYAGE 1 and VOYAGE 2. Methods In total, 1829 patients were randomized at baseline to receive guselkumab 100 mg every 8 weeks, placebo or adalimumab. Patients receiving placebo crossed over to guselkumab at week 16.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with B.
Contact B., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack